RxDoctor Payments Data

Nathan Reed, DO

Ophthalmology · Muskegon, MINPI 1306066634

Payments from drug & device makers

$874in general payments, 2019–2025

Across 29 payments — averaging $30.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$301
  • Medtronic$120
  • Aroa Biosurgery Incorporated$102
  • AbbVie$88
  • Integra Lifesciences Corporation$86
  • Omeros Corporation$59
  • plus $118 from 5 others

What the payments were for

  • Food & beverage$84597%
  • Entertainment$283%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$874 in reported general payments places this provider in the 45th percentile of 674 ophthalmology providers in Michigan.

See all ophthalmology providers in Michigan

Medicare billing

Part B allowed, 2024
$193,504
Medicare patients
583
Services billed
1,419

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RocklatanNetarsudil Mesylat/Latanoprost197$83,091
LumiganBimatoprost129$56,322
RestasisCyclosporine22$24,920
Latanoprost1,312$20,783
Prednisolone Acetate343$18,437
CombiganBrimonidine Tartrate/Timolol45$18,145
XiidraLifitegrast15$12,787
Restasis MultidoseCyclosporine15$9,297
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat387$8,891
Travoprost34$6,963
Ketorolac Tromethamine259$5,216
Timolol Maleate340$5,120
VyzultaLatanoprostene Bunod12$4,940
Ofloxacin274$3,724
SimbrinzaBrinzolamide/Brimonidine Tart13$3,155

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan, Restasis Multidose$88$108,684211 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$14$17,72727 claims
AlconSimbrinza$301$3,15513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 674 ophthalmology providers in Michigan.

Other ophthalmology in Muskegon

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →